AI in Life Science Market by Offering (End-to-End, Niche/Point, AI Tech), Application (Drug Discovery, Clinical Trials, Quality Assurance, Regulatory), Tool (Machine Learning, NLP, Computer Vision), End User (Pharma, Biotech) - Global Forecast to 2031

1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.3 STUDY SCOPE 37 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 37 1.3.2 INCLUSIONS AND EXCLUSIONS 38 1.3.3 YEARS CONSIDERED 39 1.4 CURRENCY CONSIDERED 39 1.5 STAKEHOLDERS 40 2 EXECUTIVE SUMMARY 41 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 42 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 43 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 44 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 45 3 PREMIUM INSIGHTS 46 3.1 AI IN LIFE SCIENCE MARKET OVERVIEW 46 3.2 AI IN LIFE SCIENCE MARKET, BY APPLICATION & REGION 47 3.3 AI IN LIFE SCIENCE MARKET: REGIONAL SNAPSHOT 47 4 MARKET OVERVIEW 48 4.1 INTRODUCTION 48 4.2 MARKET DYNAMICS 49 4.2.1 DRIVERS 49 4.2.1.1 Surging demand for accelerated drug discovery and R&D pipeline optimization 49 4.2.1.2 Growing cross-industry partnerships 50 4.2.1.3 Expanding applications of AI in clinical trial design, patient recruitment, and operational efficiency 51 4.2.1.4 Growing availability of large-scale biomedical datasets and advances in computing infrastructure 51 4.2.1.5 Supportive government policies, funding initiatives, and regulatory frameworks 52 4.2.2 RESTRAINTS 52 4.2.2.1 Data privacy and cybersecurity concerns 52 4.2.2.2 Algorithmic bias and clinician trust deficits 52 4.2.2.3 High implementation costs, technical complexity, and integration challenges with legacy IT systems 53 4.2.3 OPPORTUNITIES 53 4.2.3.1 Generative AI and foundation models for de novo drug design 53 4.2.3.2 Rising focus on rare disease treatments 54 4.2.3.3 Growing demand for precision and personalized medicine 54 4.2.3.4 AI integration in academic research institutes and government-backed biomedical innovation programs 55 4.2.4 CHALLENGES 55 4.2.4.1 Low data fragmentation, interoperability deficits 55 4.2.4.2 Talent scarcity and organizational readiness 56 4.3 UNMET NEEDS AND WHITE SPACES 56 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 56 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57 5 INDUSTRY TRENDS 58 5.1 PORTER’S FIVE FORCES ANALYSIS 58 5.1.1 BARGAINING POWER OF SUPPLIERS 59 5.1.2 BARGAINING POWER OF BUYERS 59 5.1.3 THREAT OF SUBSTITUTES 59 5.1.4 THREAT OF NEW ENTRANTS 59 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59 5.2 MACROECONOMIC INDICATORS 60 5.2.1 INTRODUCTION 60 5.2.2 GDP TRENDS AND FORECAST 60 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 60 5.3 VALUE CHAIN ANALYSIS 60 5.4 ECOSYSTEM ANALYSIS 62 5.5 PRICING ANALYSIS 64 5.5.1 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET (2025) 64 5.5.2 INDICATIVE PRICE FOR AI IN LIFE SCIENCE MARKET, BY REGION (2025) 64 5.6 KEY CONFERENCES AND EVENTS, 2026–2027 65 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66 5.8 INVESTMENT AND FUNDING SCENARIO 67 5.9 CASE STUDY ANALYSIS 67 5.10 IMPACT OF 2025 US TARIFF – AI IN LIFE SCIENCE MARKET 69 5.10.1 INTRODUCTION 69 5.10.2 KEY TARIFF RATES 70 5.10.3 PRICE IMPACT ANALYSIS 71 5.10.4 IMPACT ON COUNTRY/REGION 71 5.10.4.1 US 71 5.10.4.2 Europe 71 5.10.4.3 Asia Pacific 71   5.10.5 IMPACT ON END USERS 72 5.10.5.1 CRO & CDMO 72 5.10.5.2 Pharmaceutical & biotechnology companies 72 5.10.5.3 Research centers & academic institutes 72 5.10.5.4 Diagnostic companies 72 6 REGULATORY LANDSCAPE 73 6.1 REGIONAL REGULATIONS AND COMPLIANCE 73 6.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 6.1.2 NORTH AMERICA 76 6.1.3 EUROPE 77 6.1.4 ASIA PACIFIC 78 6.1.5 MIDDLE EAST & AFRICA 79 6.1.6 LATIN AMERICA 79 6.1.7 INDUSTRY STANDARDS 80 7 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTION 81 7.1 KEY EMERGING TECHNOLOGIES 81 7.1.1 GRAPH NEURAL NETWORKS 81 7.1.2 COMPUTER VISION 81 7.1.3 PREDICTIVE ANALYTICS 81 7.2 COMPLEMENTARY TECHNOLOGIES 81 7.2.1 NEXT-GENERATION SEQUENCING 82 7.2.2 REAL-WORLD EVIDENCE/REAL-WORLD DATA 82 7.2.3 PERSONALIZATION ENGINES 82 7.3 ADJACENT TECHNOLOGIES 82 7.3.1 CLOUD COMPUTING 82 7.3.2 BLOCKCHAIN 83 7.3.3 BIG DATA & ADVANCED ANALYTICS 83 7.4 TECHNOLOGY/PRODUCT ROADMAP 83 7.5 PATENT ANALYSIS 84 7.5.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 84 7.6 FUTURE APPLICATIONS 86 7.6.1 AI-DRIVEN DRUG DISCOVERY 86 7.6.2 GENOMIC ANALYSIS 87 7.6.3 PRECISION MEDICINE 87 7.6.4 VIRTUAL DRUG SCREENING 87   8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88 8.1 INTRODUCTION 88 8.2 DECISION-MAKING PROCESS 88 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 88 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 88 8.3.2 BUYING CRITERIA 89 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 90 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91 8.5.1 UNMET NEEDS 91 8.5.2 END USER EXPECTATIONS 92 8.6 MARKET PROFITABILITY 93 9 AI IN LIFE SCIENCE MARKET, BY TOOL 94 9.1 INTRODUCTION 95 9.2 MACHINE LEARNING 95 9.2.1 DEEP LEARNING 97 9.2.1.1 Convolutional neural networks 98 9.2.1.1.1 High-sensitivity medical imaging AI across oncology and radiology pathways – key driver 98 9.2.1.2 Recurrent neural networks 99 9.2.1.2.1 Sequential biological data processing drives adoption in clinical and genomic applications 99 9.2.1.3 Generative adversarial networks 100 9.2.1.3.1 Synthetic data generation to overcome life science data scarcity barriers boosts adoption 100 9.2.1.4 Graph neural networks 101 9.2.1.4.1 Graph AI architectures modeling molecular interactions to advance target and pathway discovery 101 9.2.1.5 Others 102 9.2.1.5.1 Transformer and diffusion architectures expanding deep learning frontiers in life sciences 102 9.2.2 SUPERVISED LEARNING 103 9.2.2.1 Segment driven by accurate prediction of compound potency and selectivity across diverse chemical series 103 9.2.3 REINFORCEMENT LEARNING 104 9.2.3.1 Optimized drug dosing, trial design, and autonomous laboratory systems to drive segment 104 9.2.4 UNSUPERVISED LEARNING 105 9.2.4.1 Unsupervised AI revealing hidden biological patterns within high-dimensional omics datasets 105 9.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 106 9.2.5.1 Semi-supervised and federated learning overcome data scarcity and privacy constraints 106   9.3 NATURAL LANGUAGE PROCESSING 107 9.3.1 BIOMEDICAL LLMS AND CLINICAL NLP AUTOMATING KNOWLEDGE EXTRACTION FROM UNSTRUCTURED HEALTH DATA 107 9.4 CONTEXT-AWARE PROCESSING AND COMPUTING 108 9.4.1 SEGMENT DRIVEN BY DYNAMIC, PATIENT-SPECIFIC INSIGHTS ACROSS CLINICAL WORKFLOWS 108 9.5 COMPUTER VISION 109 9.5.1 TRANSFORMATION OF PATHOLOGY, DERMATOLOGY, AND DRUG MANUFACTURING INSPECTION PROCESSES – KEY DRIVERS 109 9.6 IMAGE ANALYSIS 110 9.6.1 ACCELERATED DIGITAL PATHOLOGY, LAB IMAGING, AND DOCUMENT PROCESSING TO BOOST ADOPTION 110 9.7 OTHER TOOLS 111 10 AI IN LIFE SCIENCE MARKET, BY APPLICATION 113 10.1 INTRODUCTION 114 10.2 CLINICAL APPLICATIONS 114 10.2.1 REDUCED DEVELOPMENT TIMELINES AND IMPROVED CLINICAL SUCCESS TO DRIVE SEGMENT 114 10.2.2 DRUG DISCOVERY 116 10.2.2.1 AI-driven target identification transforming biopharma R&D productivity and success rates 116 10.2.3 MEDICAL IMAGING & DIAGNOSTICS 117 10.2.3.1 Accelerating FDA clearances and radiology digitization drives clinical AI imaging adoption 117 10.2.4 CLINICAL TRIALS 118 10.2.4.1 AI-powered trial optimization and decentralized models accelerating patient-centric research 118 10.2.5 PRECISION MEDICINE 119 10.2.5.1 Multi-Omics AI integration enabling individualized therapy selection at population scale 119 10.2.6 OTHER CLINICAL APPLICATIONS 120 10.2.6.1 AI-augmented clinical decision support expanding into pharmacovigilance and rare disease 120 10.3 NON-CLINICAL APPLICATIONS 121 10.3.1 R&D SUPPORT 122 10.3.1.1 AI-enabled literature mining and lab automation multiplying R&D throughput significantly 122 10.3.2 DATA ANALYTICS & REPORTING 123 10.3.2.1 Real-world evidence and AI analytics transforming strategic decision-making across organizations 123 10.3.3 MANUFACTURING & QUALITY ASSURANCE 124 10.3.3.1 Predictive quality AI and continuous manufacturing reduce batch failures and compliance risk 124   10.3.4 REGULATORY AFFAIRS 125 10.3.4.1 FDA and EMA AI guidance catalyzing regulatory submission automation and pharmacovigilance efficiency 125 11 AI IN LIFE SCIENCE MARKET, BY COMPONENT 126 11.1 INTRODUCTION 127 11.2 SOFTWARE 127 11.2.1 AI SOFTWARE PLATFORMS BECOMING CORE INFRASTRUCTURE FOR LIFE SCIENCE DIGITAL TRANSFORMATION 127 11.3 SERVICE 128 11.3.1 SPECIALIZED AI SERVICES BRIDGING VALIDATION AND COMPLIANCE GAPS ACROSS LIFE SCIENCE ENTERPRISES 128 12 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT 130 12.1 INTRODUCTION 131 12.2 CLOUD-BASED SOLUTIONS 131 12.2.1 HYPERSCALE CLOUD INFRASTRUCTURE ACCELERATES LIFE SCIENCE AI SCALABILITY AND COLLABORATIVE RESEARCH 131 12.3 ON-PREMISE SOLUTIONS 132 12.3.1 DATA SOVEREIGNTY AND GXP COMPLIANCE SUSTAIN ON-PREMISE AI DEPLOYMENT ACROSS REGULATED ENVIRONMENTS 132 12.4 HYBRID SOLUTIONS 133 12.4.1 HYBRID ARCHITECTURES BALANCE REGULATORY COMPLIANCE, DATA SECURITY, AND AI SCALABILITY DEMANDS 133 13 AI IN LIFE SCIENCE MARKET, BY END USER 135 13.1 INTRODUCTION 136 13.2 CRO & CDMO 136 13.2.1 AI-POWERED CROS & CDMOS COMPETE ON SPEED, QUALITY, AND DATA INTELLIGENCE DIFFERENTIATION 136 13.3 PHARMACEUTICAL COMPANIES 137 13.3.1 AI EMBEDDED ACROSS DISCOVERY, TRIALS, AND COMMERCIAL OPERATIONS BROADLY BY PHARMA LEADERS 137 13.4 BIOTECHNOLOGY COMPANIES 138 13.4.1 AI-NATIVE BIOTECH MODELS COMPRESSING DRUG DISCOVERY TIMELINES FROM YEARS TO MONTHS 138 13.5 DIAGNOSTIC COMPANIES 139 13.5.1 AI-AUGMENTED DIAGNOSTICS ELEVATE SENSITIVITY AND THROUGHPUT ACROSS MOLECULAR AND IMAGING PLATFORMS 139 13.6 ACADEMIC & GOVERNMENT LABORATORIES 140 13.6.1 PUBLIC AI RESEARCH PROGRAMS AND OPEN SCIENCE INITIATIVES BUILD FOUNDATIONAL LIFE SCIENCE INFRASTRUCTURE 140 13.7 OTHER END USERS 141   14 AI IN LIFE SCIENCE MARKET, BY OFFERING 143 14.1 INTRODUCTION 144 14.2 END-TO-END SOLUTION 144 14.2.1 INTEGRATED AI PLATFORMS COMPRESSING DRUG DEVELOPMENT TIMELINES ACROSS ENTIRE VALUE CHAINS 144 14.3 NICHE/POINT SOLUTIONS 145 14.3.1 DISEASE-SPECIFIC AI TOOLS DELIVER MEASURABLE OUTCOMES IN TARGETED RESEARCH WORKFLOWS 145 14.4 AI TECHNOLOGY 146 14.4.1 FOUNDATION MODELS AND GENERATIVE AI REDEFINE CORE SCIENTIFIC DISCOVERY CAPABILITIES 146 14.5 SERVICES 147 14.5.1 PROFESSIONAL AI SERVICES ENABLE COMPLIANT DEPLOYMENT ACROSS REGULATED LIFE SCIENCE ENVIRONMENTS 147 15 AI IN LIFE SCIENCE MARKET, BY REGION 149 15.1 INTRODUCTION 150 15.2 NORTH AMERICA 151 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 152 15.2.2 US 157 15.2.2.1 Record FDA approvals and federal funding propel AI medical device commercialization 157 15.2.3 CANADA 163 15.2.3.1 Federal AI investment and sovereign compute strategy catalyze life sciences innovation 163 15.3 EUROPE 168 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 168 15.3.2 GERMANY 174 15.3.2.1 Prescription digital health app framework propels market 174 15.3.3 FRANCE 179 15.3.3.1 National AI-health data strategy and health data hub anchor data-driven life sciences 179 15.3.4 UK 185 15.3.4.1 NHS Ten-Year Plan positions AI as core infrastructure for national care transformation 185 15.3.5 ITALY 190 15.3.5.1 National recovery plan digitization funding opens new hospital AI adoption pathways 190 15.3.6 SPAIN 195 15.3.6.1 National AI strategy and SNS digitization align life sciences sector with EU AI ambitions 195 15.3.7 REST OF EUROPE 200   15.4 ASIA PACIFIC 206 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 206 15.4.2 CHINA 212 15.4.2.1 NMPA high-end device policy and AI standardization body streamline AI commercialization 212 15.4.3 JAPAN 217 15.4.3.1 PMDA adaptive AI framework and medical DX reforms accelerate SaMD commercialization 217 15.4.4 INDIA 222 15.4.4.1 IndiaAI mission and national health data infrastructure enable population-scale AI deployment 222 15.4.5 AUSTRALIA 228 15.4.5.1 My Health Record ecosystem and TGA SaMD pathways underpin AI-ready digital infrastructure 228 15.4.6 SOUTH KOREA 233 15.4.6.1 K-Medtech ecosystem and MFDS AI regulatory guidance propel smart hospital AI adoption 233 15.4.7 REST OF ASIA PACIFIC 239 15.5 LATIN AMERICA 245 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 245 15.5.2 BRAZIL 250 15.5.2.1 RNDS National Health Network provides digital backbone for AI healthcare integration 250 15.5.3 MEXICO 256 15.5.3.1 IMSS digital transformation and National AI Strategy drive AI integration into public healthcare 256 15.5.4 REST OF LATIN AMERICA 261 15.6 MIDDLE EAST & AFRICA 267 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 267 15.6.2 GCC 273 15.6.3 SAUDI ARABIA 278 15.6.3.1 Vision 2030 health sector transformation program drives AI-enabled care delivery at scale 278 15.6.4 UAE 284 15.6.4.1 Malaffi, NABIDH interoperability and Emirati Genome Programme establish AI-ready data foundation 284 15.6.5 REST OF GCC 289 15.6.5.1 Rising demand for telehealth & virtual care to propel market 289 15.6.6 SOUTH AFRICA 294 15.6.6.1 National health insurance framework and digital health programs catalyze AI market entry 294 15.6.7 REST OF MIDDLE EAST & AFRICA 299   16 COMPETITIVE LANDSCAPE 305 16.1 OVERVIEW 305 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 305 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET 306 16.3 REVENUE ANALYSIS 308 16.4 MARKET SHARE ANALYSIS, 2025 309 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 311 16.5.1 STARS 311 16.5.2 EMERGING LEADERS 311 16.5.3 PERVASIVE PLAYERS 311 16.5.4 PARTICIPANTS 312 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 313 16.5.5.1 Company footprint 313 16.5.5.2 Region footprint 314 16.5.5.3 Offering footprint 315 16.5.5.4 Application footprint 316 16.5.5.5 End user footprint 317 16.5.5.6 Tools footprint 318 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 319 16.6.1 PROGRESSIVE COMPANIES 319 16.6.2 RESPONSIVE COMPANIES 319 16.6.3 DYNAMIC COMPANIES 319 16.6.4 STARTING BLOCKS 319 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 321 16.6.5.1 Detailed list of key startups/SMEs 321 16.6.5.2 Competitive benchmarking of startups/SMEs 322 16.7 VALUATION & FINANCIAL METRICS 323 16.7.1 FINANCIAL METRICS 323 16.7.2 COMPANY VALUATION 323 16.8 BRAND/SOFTWARE COMPARISON 324 16.9 COMPETITIVE SCENARIO 325 16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 325 16.9.2 DEALS 326 16.9.3 EXPANSIONS 327   17 COMPANY PROFILES 328 17.1 KEY PLAYERS 328 17.1.1 NVIDIA CORPORATION 328 17.1.1.1 Business overview 328 17.1.1.2 Products/Solutions offered 329 17.1.1.3 Recent developments 330 17.1.1.3.1 Product launches & enhancements 330 17.1.1.3.2 Deals 331 17.1.1.3.3 Other developments 334 17.1.1.4 MnM view 334 17.1.1.4.1 Key strengths 334 17.1.1.4.2 Strategic choices 334 17.1.1.4.3 Weaknesses and competitive threats 335 17.1.2 ILLUMINA, INC. 336 17.1.2.1 Business overview 336 17.1.2.2 Products/Solutions offered 337 17.1.2.3 Recent developments 338 17.1.2.3.1 Product launches & enhancements 338 17.1.2.3.2 Deals 340 17.1.2.4 MnM view 341 17.1.2.4.1 Key strengths 341 17.1.2.4.2 Strategic choices 341 17.1.2.4.3 Weaknesses and competitive threats 342 17.1.3 TEMPUS AI, INC. 343 17.1.3.1 Business overview 343 17.1.3.2 Products offered 344 17.1.3.3 Recent developments 345 17.1.3.3.1 Deals 345 17.1.3.3.2 Other developments 345 17.1.4 RECURSION 346 17.1.4.1 Business overview 346 17.1.4.2 Products/Solutions offered 347 17.1.4.3 Recent developments 348 17.1.4.3.1 Product launches & enhancements 348 17.1.4.3.2 Deals 348 17.1.4.3.3 Expansions 350 17.1.4.4 MnM view 350 17.1.4.4.1 Key strengths 350 17.1.4.4.2 Strategic choices 351 17.1.4.4.3 Weaknesses and competitive threats 351   17.1.5 DASSAULT SYSTÈMES SE 352 17.1.5.1 Business overview 352 17.1.5.2 Products offered 353 17.1.5.3 Recent developments 354 17.1.5.3.1 Product launches & enhancements 354 17.1.5.3.2 Deals 354 17.1.5.3.3 Other developments 355 17.1.6 SCHRÖDINGER, INC. 356 17.1.6.1 Business overview 356 17.1.6.2 Products/Solutions offered 357 17.1.6.3 Recent developments 358 17.1.6.3.1 Deals 358 17.1.6.3.2 Other Developments 359 17.1.7 DATA4CURE, INC. 360 17.1.7.1 Business overview 360 17.1.7.2 Products offered 360 17.1.7.3 Recent developments 361 17.1.7.3.1 Product launches & enhancements 361 17.1.7.3.2 Other developments 361 17.1.8 MICROSOFT CORPORATION 362 17.1.8.1 Business overview 362 17.1.8.2 Products offered 363 17.1.8.3 Recent developments 364 17.1.8.3.1 Product launches & enhancements 364 17.1.8.3.2 Deals 365 17.1.8.3.3 Other developments 365 17.1.9 INSILICO MEDICINE 366 17.1.9.1 Business overview 366 17.1.9.2 Products/Services offered 366 17.1.9.3 Recent developments 367 17.1.9.3.1 Product launches & enhancements 367 17.1.9.3.2 Deals 368 17.1.9.3.3 Other developments 370 17.1.9.3.4 Expansions 370 17.1.10 EUROFINS DISCOVERY 371 17.1.10.1 Business overview 371 17.1.10.2 Products offered 371 17.1.10.3 Recent developments 372 17.1.10.3.1 Product launches & approvals 372 17.1.10.3.2 Deals 372   17.1.11 BENEVOLENTAI LIMITED 373 17.1.11.1 Business overview 373 17.1.11.2 Products offered 373 17.1.11.3 Recent developments 374 17.1.11.3.1 Deals 374 17.1.12 OWKIN 375 17.1.12.1 Business overview 375 17.1.12.2 Products offered 375 17.1.12.3 Recent developments 376 17.1.12.3.1 Product launches & approvals 376 17.1.12.3.2 Deals 377 17.1.12.3.3 Other developments 377 17.1.13 PATHAI 378 17.1.13.1 Business overview 378 17.1.13.2 Products offered 378 17.1.13.3 Recent developments 379 17.1.13.3.1 Product launches & approvals 379 17.1.13.3.2 Deals 379 17.1.14 AIDOC MEDICAL LTD. 380 17.1.14.1 Business overview 380 17.1.14.2 Products offered 380 17.1.14.3 Recent developments 381 17.1.14.3.1 Product launches & approvals 381 17.1.14.3.2 Other developments 382 17.1.15 QURE.AI 383 17.1.15.1 Business overview 383 17.1.15.2 Products offered 383 17.1.15.3 Recent developments 384 17.1.15.3.1 Product launches & approvals 384 17.1.16 DEEP GENOMICS 385 17.1.16.1 Business overview 385 17.1.16.2 Products offered 385 17.1.16.3 Recent developments 386 17.1.16.3.1 Expansions 386 17.1.17 SOPHIA GENETICS SA 387 17.1.17.1 Business overview 387 17.1.17.2 Products offered 388 17.1.17.3 Recent developments 389 17.1.17.3.1 Product launches & enhancements 389 17.1.17.3.2 Deals 389   17.1.18 UNLEARN.AI 390 17.1.18.1 Business overview 390 17.1.18.2 Products offered 390 17.1.18.3 Recent developments 391 17.1.18.3.1 Deals 391 17.1.19 VERGE GENOMICS 392 17.1.19.1 Business overview 392 17.1.19.2 Products offered 392 17.1.19.3 Recent developments 393 17.1.19.3.1 Deals 393 17.2 OTHER PLAYERS 394 17.2.1 SYNTHIO LABS LTD 394 17.2.2 BIOPTIMUS 394 17.2.3 KARYON BIO 395 17.2.4 COUNTERFORCE HEALTH 395 17.2.5 PROMISE BIO 396 18 RESEARCH METHODOLOGY 397 18.1 RESEARCH APPROACH 397 18.1.1 SECONDARY RESEARCH 398 18.1.1.1 Key data from secondary sources 399 18.1.2 PRIMARY RESEARCH 399 18.1.2.1 Primary sources 400 18.1.2.2 Key data from primary sources 401 18.1.2.3 Breakdown of primary interviews 401 18.1.2.4 Insights from primary experts 402 18.2 RESEARCH METHODOLOGY DESIGN 402 18.3 MARKET SIZE ESTIMATION 404 18.4 DATA TRIANGULATION 409 18.5 RESEARCH ASSUMPTIONS 410 18.6 RESEARCH LIMITATIONS 410 18.6.1 METHODOLOGY-RELATED 410 18.6.2 SCOPE-RELATED 411 18.7 RISK ASSESSMENT 411 19 APPENDIX 412 19.1 DISCUSSION GUIDE 412 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 418 19.3 CUSTOMIZATION OPTIONS 420 19.4 RELATED REPORTS: 420 19.5 AUTHOR DETAILS 421

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 40 TABLE 2 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS 59 TABLE 3 AI IN LIFE SCIENCE MARKET: ROLE IN ECOSYSTEM 63 TABLE 4 CASE 1: GENERATIVE AI ACCELERATES DRUG DISCOVERY, CLINICAL RESEARCH, AND OPERATIONAL EFFICIENCY IN LIFE SCIENCES 67 TABLE 5 CASE 2: JOHNSON & JOHNSON EXPANDS AI INTEGRATION ACROSS DRUG DISCOVERY, SURGICAL INNOVATION, AND HEALTHCARE OPERATIONS 68 TABLE 6 CASE 3: AI-DRIVEN DRUG DISCOVERY AND CLINICAL OPTIMIZATION ACCELERATE INNOVATION IN LIFE SCIENCES 69 TABLE 7 US ADJUSTED RECIPROCAL TARIFF RATES 70 TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN LIFE SCIENCE MARKET 84 TABLE 14 AI IN LIFE SCIENCE MARKET: KEY PATENTS/PATENT APPLICATIONS 86 TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 89 TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS 90 TABLE 17 UNMET NEEDS IN AI IN LIFE SCIENCE MARKET 91 TABLE 18 END USER EXPECTATIONS IN AI IN LIFE SCIENCE MARKET 92 TABLE 19 AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 95 TABLE 20 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 96 TABLE 21 AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY REGION, 2024–2031 (USD MILLION) 96 TABLE 22 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 97 TABLE 23 AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY REGION, 2024–2031 (USD MILLION) 98 TABLE 24 AI IN LIFE SCIENCE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION) 99 TABLE 25 AI IN LIFE SCIENCE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION) 100 TABLE 26 AI IN LIFE SCIENCE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2024–2031 (USD MILLION) 101 TABLE 27 AI IN LIFE SCIENCE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION) 102 TABLE 28 AI IN LIFE SCIENCE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION) 103 TABLE 29 AI IN LIFE SCIENCE MARKET FOR SUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION) 104 TABLE 30 AI IN LIFE SCIENCE MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2024–2031 (USD MILLION) 105 TABLE 31 AI IN LIFE SCIENCE MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 32 AI IN LIFE SCIENCE MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 33 AI IN LIFE SCIENCE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 34 AI IN LIFE SCIENCE MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 35 AI IN LIFE SCIENCE MARKET FOR COMPUTER VISION, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 36 AI IN LIFE SCIENCE MARKET FOR IMAGE ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 37 AI IN LIFE SCIENCE MARKET FOR OTHER TOOLS, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 38 AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 114 TABLE 39 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 115 TABLE 40 AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 41 AI IN LIFE SCIENCE MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 42 AI IN LIFE SCIENCE MARKET FOR MEDICAL IMAGING AND DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 43 AI IN LIFE SCIENCE MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 44 AI IN LIFE SCIENCE MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 45 AI IN LIFE SCIENCE MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 46 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 121 TABLE 47 AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 48 AI IN LIFE SCIENCE MARKET FOR R&D SUPPORT, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 49 AI IN LIFE SCIENCE MARKET FOR DATA ANALYTICS AND REPORTING, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 50 AI IN LIFE SCIENCE MARKET FOR MANUFACTURING & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 51 AI IN LIFE SCIENCE MARKET FOR REGULATORY AFFAIRS, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 52 AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 127 TABLE 53 AI IN LIFE SCIENCE MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 54 AI IN LIFE SCIENCE MARKET FOR SERVICE, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 55 AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION) 131 TABLE 56 AI IN LIFE SCIENCE MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 57 AI IN LIFE SCIENCE MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 58 AI IN LIFE SCIENCE MARKET FOR HYBRID SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 59 AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 136 TABLE 60 AI IN LIFE SCIENCE MARKET FOR CRO & CDMO, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 61 AI IN LIFE SCIENCE MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 62 AI IN LIFE SCIENCE MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 63 AI IN LIFE SCIENCE MARKET FOR DIAGNOSTIC COMPANIES, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 64 AI IN LIFE SCIENCE MARKET FOR ACADEMIC AND GOVERNMENT LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 65 AI IN LIFE SCIENCE MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 66 AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 144 TABLE 67 AI IN LIFE SCIENCE MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 68 AI IN LIFE SCIENCE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 69 AI IN LIFE SCIENCE MARKET FOR AI TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 70 AI IN LIFE SCIENCE MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 71 AI IN LIFE SCIENCE MARKET, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 72 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 73 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 152 TABLE 74 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 153 TABLE 75 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 153 TABLE 76 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 77 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 154 TABLE 78 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 155 TABLE 79 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 80 NORTH AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 81 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 156 TABLE 82 NORTH AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 157 TABLE 83 US: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 158 TABLE 84 US: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 158 TABLE 85 US: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 86 US: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 87 US: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 160 TABLE 88 US: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 160 TABLE 89 US: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 90 US: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 91 US: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 162 TABLE 92 US: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 162 TABLE 93 CANADA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 163 TABLE 94 CANADA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 164 TABLE 95 CANADA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 96 CANADA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 97 CANADA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 165 TABLE 98 CANADA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 166 TABLE 99 CANADA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 100 CANADA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 101 CANADA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 167 TABLE 102 CANADA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 168 TABLE 103 EUROPE: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 104 EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 169 TABLE 105 EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 170 TABLE 106 EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 107 EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 108 EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 171 TABLE 109 EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 172 TABLE 110 EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 111 EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 112 EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 173 TABLE 113 EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 174 TABLE 114 GERMANY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 175 TABLE 115 GERMANY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 175 TABLE 116 GERMANY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 117 GERMANY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 118 GERMANY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 177 TABLE 119 GERMANY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 177 TABLE 120 GERMANY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 121 GERMANY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 122 GERMANY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 179 TABLE 123 GERMANY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 124 FRANCE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 180 TABLE 125 FRANCE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 181 TABLE 126 FRANCE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 127 FRANCE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 128 FRANCE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 182 TABLE 129 FRANCE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 183 TABLE 130 FRANCE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 131 FRANCE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 132 FRANCE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 184 TABLE 133 FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 185 TABLE 134 UK: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 186 TABLE 135 UK: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186 TABLE 136 UK: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 137 UK: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 138 UK: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 188 TABLE 139 UK: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 188 TABLE 140 UK: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 141 UK: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 142 UK: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 190 TABLE 143 UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 190 TABLE 144 ITALY: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 191 TABLE 145 ITALY: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 191 TABLE 146 ITALY: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 147 ITALY: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 148 ITALY: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 193 TABLE 149 ITALY: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 193 TABLE 150 ITALY: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 151 ITALY: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 152 ITALY: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 195 TABLE 153 ITALY: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 154 SPAIN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196 TABLE 155 SPAIN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 196 TABLE 156 SPAIN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 157 SPAIN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 158 SPAIN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 198 TABLE 159 SPAIN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 198 TABLE 160 SPAIN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 161 SPAIN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 162 SPAIN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 200 TABLE 163 SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 164 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 201 TABLE 165 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 201 TABLE 166 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 167 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 168 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 203 TABLE 169 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 203 TABLE 170 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 171 REST OF EUROPE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 172 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 205 TABLE 173 REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 205 TABLE 174 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 175 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 208 TABLE 176 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 208 TABLE 177 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 178 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 179 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 209 TABLE 180 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 210 TABLE 181 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 182 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 183 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 211 TABLE 184 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 185 CHINA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 213 TABLE 186 CHINA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213 TABLE 187 CHINA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 188 CHINA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 189 CHINA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 214 TABLE 190 CHINA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 215 TABLE 191 CHINA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 192 CHINA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 193 CHINA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 216 TABLE 194 CHINA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 217 TABLE 195 JAPAN: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 218 TABLE 196 JAPAN: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 197 JAPAN: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 198 JAPAN: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 199 JAPAN: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 220 TABLE 200 JAPAN: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 220 TABLE 201 JAPAN: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 202 JAPAN: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 203 JAPAN: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 222 TABLE 204 JAPAN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 205 INDIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 223 TABLE 206 INDIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 224 TABLE 207 INDIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 208 INDIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 209 INDIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 225 TABLE 210 INDIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 226 TABLE 211 INDIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 212 INDIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 213 INDIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 227 TABLE 214 INDIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 228 TABLE 215 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 229 TABLE 216 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 229 TABLE 217 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 218 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 219 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 231 TABLE 220 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 231 TABLE 221 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 222 AUSTRALIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 223 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 233 TABLE 224 AUSTRALIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 233 TABLE 225 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 234 TABLE 226 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 227 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 228 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 229 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 236 TABLE 230 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 237 TABLE 231 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 232 SOUTH KOREA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 233 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 238 TABLE 234 SOUTH KOREA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 239 TABLE 235 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 240 TABLE 236 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 240 TABLE 237 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 238 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 239 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 242 TABLE 240 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 242 TABLE 241 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 242 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 243 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 244 TABLE 244 REST OF ASIA PACIFIC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 244 TABLE 245 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 246 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 246 TABLE 247 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 248 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 249 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 250 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 247 TABLE 251 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 248 TABLE 252 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 253 LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 254 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 249 TABLE 255 LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 250 TABLE 256 BRAZIL: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 251 TABLE 257 BRAZIL: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 251 TABLE 258 BRAZIL: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 259 BRAZIL: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 260 BRAZIL: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 253 TABLE 261 BRAZIL: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 253 TABLE 262 BRAZIL: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 263 BRAZIL: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 264 BRAZIL: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 255 TABLE 265 BRAZIL: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 255 TABLE 266 MEXICO: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 256 TABLE 267 MEXICO: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257 TABLE 268 MEXICO: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 269 MEXICO: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 270 MEXICO: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 258 TABLE 271 MEXICO: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 259 TABLE 272 MEXICO: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 273 MEXICO: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 274 MEXICO: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 260 TABLE 275 MEXICO: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 261 TABLE 276 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 262 TABLE 277 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 262 TABLE 278 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 279 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 280 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 264 TABLE 281 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 264 TABLE 282 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 283 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 284 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 266 TABLE 285 REST OF LATIN AMERICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 266 TABLE 286 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268 TABLE 287 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 268 TABLE 288 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 269 TABLE 289 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 290 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 291 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 270 TABLE 292 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 271 TABLE 293 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 294 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 295 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 272 TABLE 296 MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 297 GCC: AI IN LIFE SCIENCE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 298 GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 274 TABLE 299 GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274 TABLE 300 GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 301 GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 302 GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 275 TABLE 303 GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 276 TABLE 304 GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 305 GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 306 GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 277 TABLE 307 GCC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 308 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 279 TABLE 309 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 279 TABLE 310 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 311 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 312 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 281 TABLE 313 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 281 TABLE 314 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 315 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 316 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 283 TABLE 317 SAUDI ARABIA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 318 UAE: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 285 TABLE 319 UAE: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 285 TABLE 320 UAE: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 321 UAE: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 322 UAE: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 286 TABLE 323 UAE: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 287 TABLE 324 UAE: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 325 UAE: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 326 UAE: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 288 TABLE 327 UAE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 328 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 290 TABLE 329 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 290 TABLE 330 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 331 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 332 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 291 TABLE 333 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 292 TABLE 334 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 335 REST OF GCC: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 336 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 293 TABLE 337 REST OF GCC: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 294 TABLE 338 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 295 TABLE 339 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 295 TABLE 340 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 341 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 342 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 297 TABLE 343 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 297 TABLE 344 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 345 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 346 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 299 TABLE 347 SOUTH AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 299 TABLE 348 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 300 TABLE 349 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 300 TABLE 350 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 351 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR NON-CLINICAL APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 301 TABLE 352 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY COMPONENT, 2024–2031 (USD MILLION) 302 TABLE 353 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY TOOL, 2024–2031 (USD MILLION) 302 TABLE 354 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 355 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 356 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 304 TABLE 357 REST OF MIDDLE EAST & AFRICA: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031 (USD MILLION) 304 TABLE 358 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, JANUARY 2023–APRIL 2026 306 TABLE 359 AI IN LIFE SCIENCE MARKET: DEGREE OF COMPETITION 310 TABLE 360 AI IN LIFE SCIENCE MARKET: REGION FOOTPRINT 314 TABLE 361 AI IN LIFE SCIENCE MARKET: OFFERING FOOTPRINT 315 TABLE 362 AI IN LIFE SCIENCE MARKET: APPLICATION FOOTPRINT 316 TABLE 363 AI IN LIFE SCIENCE MARKET: END USER FOOTPRINT 317 TABLE 364 AI IN LIFE SCIENCE MARKET: TOOLS FOOTPRINT 318 TABLE 365 AI IN LIFE SCIENCE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 321 TABLE 366 AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 322 TABLE 367 AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING 322 TABLE 368 AI IN LIFE SCIENCE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY APPLICATION 322 TABLE 369 AI IN LIFE SCIENCE MARKET: SOLUTION LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 325 TABLE 370 AI IN LIFE SCIENCE MARKET: DEALS, JANUARY 2023–APRIL 2026 326 TABLE 371 AI IN LIFE SCIENCE MARKET: EXPANSIONS, JANUARY 2023–APRIL 2026 327 TABLE 372 NVIDIA CORPORATION: COMPANY OVERVIEW 328 TABLE 373 NVIDIA CORPORATION: PRODUCTS /SOLUTIONS OFFERED 329 TABLE 374 NVIDIA CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 330 TABLE 375 NVIDIA CORPORATION: DEALS, JANUARY 2023– APRIL 2026 331 TABLE 376 NVIDIA CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 334 TABLE 377 ILLUMINA, INC.: COMPANY OVERVIEW 336 TABLE 378 ILLUMINA, INC.: PRODUCTS /SOLUTIONS OFFERED 337 TABLE 379 ILLUMINA, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 338 TABLE 380 ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026 340 TABLE 381 TEMPUS AI, INC.: COMPANY OVERVIEW 343 TABLE 382 TEMPUS AI, INC.: PRODUCTS OFFERED 344 TABLE 383 TEMPUS AI, INC.: DEALS, JANUARY 2023–APRIL 2026 345 TABLE 384 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 345 TABLE 385 RECURSION: COMPANY OVERVIEW 346 TABLE 386 RECURSION: PRODUCTS /SOLUTIONS OFFERED 347 TABLE 387 RECURSION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 348 TABLE 388 RECURSION: DEALS, JANUARY 2023– APRIL 2026 348 TABLE 389 RECURSION: EXPANSIONS, JANUARY 2023–APRIL 2026 350 TABLE 390 DASSAULT SYSTÈMES SE: COMPANY OVERVIEW 352 TABLE 391 DASSAULT SYSTÈMES SE: PRODUCTS OFFERED 353 TABLE 392 DASSAULT SYSTÈMES SE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 354 TABLE 393 DASSAULT SYSTÈMES SE: DEALS, JANUARY 2023–APRIL 2026 354 TABLE 394 DASSAULT SYSTÈMES SE: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 355 TABLE 395 SCHRÖDINGER, INC.: COMPANY OVERVIEW 356 TABLE 396 SCHRÖDINGER, INC.: PRODUCTS /SOLUTIONS OFFERED 357 TABLE 397 SCHRÖDINGER, INC.: DEALS, JANUARY 2023–APRIL 2026 358 TABLE 398 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023-APRIL 2026 359 TABLE 399 DATA4CURE, INC.: COMPANY OVERVIEW 360 TABLE 400 DATA4CURE, INC.: PRODUCTS OFFERED 360 TABLE 401 DATA4CURE, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 361 TABLE 402 DATA4CURE, INC.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 361 TABLE 403 MICROSOFT CORPORATION: COMPANY OVERVIEW 362 TABLE 404 MICROSOFT CORPORATION: PRODUCTS OFFERED 363 TABLE 405 MICROSOFT CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 364 TABLE 406 MICROSOFT CORPORATION: DEALS, JANUARY 2023–APRIL 2026 365 TABLE 407 MICROSOFT CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 365 TABLE 408 INSILICO MEDICINE: COMPANY OVERVIEW 366 TABLE 409 INSILICO MEDICINE: PRODUCTS /SERVICES OFFERED 366 TABLE 410 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–APRIL 2026 367 TABLE 411 INSILICO MEDICINE: DEALS, JANUARY 2023–APRIL 2026 368 TABLE 412 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2023-APRIL 2026 370 TABLE 413 INSILICO MEDICINE: EXPANSIONS, JANUARY 2023–APRIL 2026 370 TABLE 414 EUROFINS DISCOVERY: COMPANY OVERVIEW 371 TABLE 415 EUROFINS DISCOVERY: PRODUCTS OFFERED 371 TABLE 416 EUROFINS DISCOVERY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 372 TABLE 417 EUROFINS DISCOVERY: DEALS, JANUARY 2023–APRIL 2026 372 TABLE 418 BENEVOLENTAI LIMITED: COMPANY OVERVIEW 373 TABLE 419 BENEVOLENTAI LIMITED: PRODUCTS OFFERED 373 TABLE 420 BENEVOLENTAI LIMITED: DEALS, JANUARY 2023–APRIL 2026 374 TABLE 421 OWKIN: COMPANY OVERVIEW 375 TABLE 422 OWKIN: PRODUCTS OFFERED 375 TABLE 423 OWKIN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 376 TABLE 424 OWKIN: DEALS, JANUARY 2023–APRIL 2026 377 TABLE 425 OWKIN: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 377 TABLE 426 PATHAI: COMPANY OVERVIEW 378 TABLE 427 PATHAI: PRODUCTS OFFERED 378 TABLE 428 PATHAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 379 TABLE 429 PATHAI: DEALS, JANUARY 2023–APRIL 2026 379 TABLE 430 AIDOC MEDICAL LTD.: COMPANY OVERVIEW 380 TABLE 431 AIDOC MEDICAL LTD.: PRODUCTS OFFERED 380 TABLE 432 AIDOC MEDICAL LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 381 TABLE 433 AIDOC MEDICAL LTD.: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 382 TABLE 434 QURE.AI: COMPANY OVERVIEW 383 TABLE 435 QURE.AI: PRODUCTS OFFERED 383 TABLE 436 QURE.AI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 384 TABLE 437 DEEP GENOMICS: COMPANY OVERVIEW 385 TABLE 438 DEEP GENOMICS: PRODUCTS OFFERED 385 TABLE 439 DEEP GENOMICS: EXPANSIONS, JANUARY 2023–APRIL 2026 386 TABLE 440 SOPHIA GENETICS SA: COMPANY OVERVIEW 387 TABLE 441 SOPHIA GENETICS SA: PRODUCTS OFFERED 388 TABLE 442 SOPHIA GENETICS SA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–APRIL 2026 389 TABLE 443 SOPHIA GENETICS SA: DEALS, JANUARY 2023–APRIL 2026 389 TABLE 444 UNLEARN.AI: COMPANY OVERVIEW 390 TABLE 445 UNLEARN.AI: PRODUCTS OFFERED 390 TABLE 446 UNLEARN.AI: DEALS, JANUARY 2023–APRIL 2026 391 TABLE 447 VERGE GENOMICS: COMPANY OVERVIEW 392 TABLE 448 VERGE GENOMICS: PRODUCTS OFFERED 392 TABLE 449 VERGE GENOMICS: DEALS, JANUARY 2023–APRIL 2026 393 TABLE 450 SYNTHIO LABS LTD: COMPANY OVERVIEW 394 TABLE 451 BIOPTIMUS: COMPANY OVERVIEW 394 TABLE 452 KARYON BIO: COMPANY OVERVIEW 395 TABLE 453 COUNTERFORCE HEALTH: COMPANY OVERVIEW 395 TABLE 454 PROMISE BIO: COMPANY OVERVIEW 396 FIGURE 1 MARKET SCENARIO 41 FIGURE 2 GLOBAL AI IN LIFE SCIENCE MARKET, 2024–2031 42 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2023–2026 42 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF AI IN LIFE SCIENCE MARKET 43 FIGURE 5 HIGH-GROWTH SEGMENTS IN AI IN LIFE SCIENCE MARKET, 2026–2031 44 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN LIFE SCIENCE MARKET DURING FORECAST PERIOD 45 FIGURE 7 GROWING ADOPTION OF PRECISION MEDICINE AND AI IN DRUG DISCOVERY TO DRIVE MARKET 46 FIGURE 8 CLINICAL APPLICATIONS IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 47 FIGURE 9 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 47 FIGURE 10 AI IN LIFE SCIENCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49 FIGURE 11 AI IN LIFE SCIENCE MARKET: PORTER’S FIVE FORCES ANALYSIS 58 FIGURE 12 AI IN LIFE SCIENCE MARKET: VALUE CHAIN ANALYSIS (2025) 61 FIGURE 13 AI IN LIFE SCIENCE MARKET: ECOSYSTEM ANALYSIS 63 FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 66 FIGURE 15 TOTAL FUNDING OF PLAYERS IN AI IN LIFE SCIENCE MARKET 67 FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN LIFE SCIENCE MARKET 84 FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN LIFE SCIENCE MARKET (JANUARY 2015 TO DECEMBER 2025) 85 FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 89 FIGURE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS 90 FIGURE 20 NORTH AMERICA: AI IN LIFE SCIENCE MARKET SNAPSHOT 151 FIGURE 21 ASIA PACIFIC: AI IN LIFE SCIENCE MARKET SNAPSHOT 207 FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN LIFE SCIENCE MARKET, 2021–2025 (USD MILLION) 308 FIGURE 23 AI IN LIFE SCIENCE MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 310 FIGURE 24 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 312 FIGURE 25 AI IN LIFE SCIENCE MARKET: COMPANY FOOTPRINT 313 FIGURE 26 AI IN LIFE SCIENCE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 320 FIGURE 27 EV/EBITDA OF KEY VENDORS 323 FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 323 FIGURE 29 AI IN LIFE SCIENCE MARKET: BRAND/SOFTWARE COMPARATIVE ANALYSIS 324 FIGURE 30 NVIDIA CORPORATION: COMPANY SNAPSHOT (2025) 329 FIGURE 31 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 337 FIGURE 32 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025) 343 FIGURE 33 RECURSION: COMPANY SNAPSHOT (2024) 347 FIGURE 34 DASSAULT SYSTÈMES SE: COMPANY SNAPSHOT (2025) 353 FIGURE 35 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2024) 357 FIGURE 36 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2025) 363 FIGURE 37 SOPHIA GENETICS SA: COMPANY SNAPSHOT (2025) 388 FIGURE 38 RESEARCH DESIGN 397 FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 403 FIGURE 40 BOTTOM-UP APPROACH 404 FIGURE 41 TOP-DOWN APPROACH 405 FIGURE 42 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 406 FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 407 FIGURE 44 DATA TRIANGULATION 409